The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). (Q36130527)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). |
scientific article |
Statements
1 reference
The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). (English)
1 reference
Joanna Xing
1 reference
Ruixin Liu
1 reference
Mingzhao Xing
1 reference
Barry Trink
1 reference
23 December 2010
1 reference
1 reference
958-962
1 reference
Identifiers
1 reference
1 reference
1 reference